The facts about participating in clinical research and our ongoing studies:
First and foremost your safety is our top priority. Participating in clinical research gives you access to the latest medical and scientific innovations in medicine as well as compensates the participant(s) for time and travel. Most importantly, you are advancing medical science by contributing to the development of vital new medicines and paving the way for these new medicines to reach the market.
Please let us know if you are interested in participating in a research study. Study participants receive medical care, lab tests, and study medication at no cost, and are compensated for their participation. Transportation can be provided.
For more information, please call: 954-366-0277.
CURRENTLY ENROLLING STUDIES
For more information, please call: 954-366-0277.
Merck – APECS: Memory Loss
A two-year study with a new oral drug as a potential disease-modifying therapy in patients 50 and 85 years old who have been experiencing memory loss for a year.
Lilly/LZBE: Memory Loss
A two year study to evaluate a potential disease-modifying treatment given monthly by infusion in patients 50 to 85 years old with memory loss.
Biogen/EMERGE: Alzheimer’s Disease
A two-year study to evaluate a potential disease modifying treatment given monthly by intravenous infusion on the effect of passive immunization on the progression of cognitive impairment/mild Alzheimer’s Disease in patients who are 55 to 90 years old.
Lilly/DAYBREAK: Alzheimer’s Disease
A 18 Month study to evaluate an oral potential disease modifying therapy in patients 55-85 years old with Mild Alzheimer’s Disease.
Colucid 302/SPARTAN: Migraine
Acute treatment- a study to evaluate a Novel abortive migraine medication (with optional 12 month open label extension).
Lilly/CGAH: Migraine Prevention
A 16 month study evaluating the effectiveness of a monthly injection in patients 18 to 65 who suffer from migraine headaches with or without aura.
San Bio-Sunovion: Post Stroke Stem cell study
Stem cell study for patients 18 to 75 years old with a motor deficit from a stroke at least 6 months old and no longer than 5 years ago. Study duration is approximately 1 year.
Lead Study Coordinator: Lucy Vargas
954-981-4491 / email@example.com
Forest – ASCENT COPD: Moderate to Severe COPD with High Cardiovascular Risk
A three-year post-marketing study to evaluate the effect of aclidinium bromide (Tudorza Pressair) on long-term cardiovascular safety and COPD attacks in patients 40 years old or older who are current or former smokers, with moderate to very severe COPD and a history of cardiovascular or cerebrovascular disease and/or significant cardiovascular risk. This medicine is already FDA approved!
Glaxo SmithKline – IMPACT: Chronic Obstructive Pulmonary Disease
A one-year study comparing the efficacy, safety and tolerability of the investigational fixed dose triple combination therapy fluticasone furoate / umeclidinium / vilanterol trifentate (FF / UMEC / VI) compared with one of the FDA approved fixed dose dual combinations of Breo Ellipta (fluticasone furoate / vilanternol), a medicine similar to Advair, and Anoro Ellipta (umeclidinium / vilanterol) a medicine similar to Spiriva plus a fast-acting broncho-dilator; all administered once-daily in the morning with a dry powder inhaler in patients 40 years old or older with chronic obstructive pulmonary disease who are current or former smokers of at least 10 years.
Study Coordinator: Becky Nembhard
954-306-8163 / firstname.lastname@example.org
CARMELINA: Boehringer-Ingelheim: Diabetics with a high risk of heart or kidney disease
A multi-year study to evaluate an approved Type II diabetes medication in diabetic patients with a high risk of heart and/or kidney disease.
TACT: Armetheon: Chronic Anticoagulation (“blood thinners”)
Up to 2 years study comparing a novel new Vitamin K antagonist (“blood thinner”) with warfarin in patients requiring long-term anticoagulation.
Clinical Study Coordinators:
Michele Kroll Fistel, LPN, CCRC; Dalia Ramos, RMA, CCRP; Fanny Gully, CRC; Magdeli Ramos, CCRC
Acorda Therapeutics/Civitas – LIDS: Parkinson’s Disease with Levodopa Induced Dyskinesias
A 12-month long study to assess safety and efficacy of a Levodopa Inhalation Powder in Parkinson’s Disease Patients With Motor Response Fluctuations (OFF Phenomena) Compared to an Observational Cohort Control
Study to assess ALD403 in the prevention of migraine headache in frequent episodic migraineurs.
Amgen – 20120296 STRIVE: Migraine Prevention
Up to 71-week study to Evaluate the Efficacy and Safety of an investigation medication in Migraine Prevention. The planned length of participation in the study for an individual subject is up to 71 weeks, which includes the following:
- Initial screening phase of up to 3 weeks
- 4-week baseline phase
- 24-week double-blind treatment phase
BAN2401-G000-201 – Alzheimer’s Disease
A placebo-controlled, double-blind, parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding study to evaluate safety, tolerability and efficacy of BAN2401 in subjects with early alzheimer’s disease.
Celgene – Diabetic Peripheral Neuropathy
An Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy
Biogen 109MS414 MITIGATE
An 18-week long study to evaluate whether montelukast can reduce the severity of GI events in subjects with relapsing forms of MS taking TECFIDERA®
CoLucid – SAMARAI
11-week long study of Lasmitadan compared to placebo in the Acute Treatment of Migraine
Daiichi Sankyo: Fibromyalgia
A 21-week long study with optional long-term, open label extension to test effectiveness of an investigational drug compared to an FDA approved drug on fibromyalgia pain.
Eli Lilly – AMARANTH: Early Alzheimer’s Disease (MMSE 21-30)
A 24-month long study to evaluate a potential disease modifying therapy, oral formulation, in patients between 55 and 85 years old with early Alzheimer’s disease.
Pfizer TANGO: Chronic Low Back Pain
56-week long, randomized, double-blind, placebo and active controlled study of the analgesic efficacy and safety of Tanezumab in subjects with chronic low back pain
Lundbeck – STARBEAM: Mild to Moderate Alzheimer’s disease (MMSE 12-22)
A 28-week long study with optional long term, open-label extension in patients with mild-moderate Alzheimer’s disease treated with donepezil as adjunctive therapy.
Mallinckrodt: Multiple Sclerosis
Observational study using H.P. Acthar Gel to treat patients with multiple sclerosis experiencing exacerbations
Neurim Pharmaceuticals Ltd. – reCOGNITION Mild Alzheimer’s disease (MMSE 21-26)
This study is a Phase 2, randomized, placebo controlled, dose ranging study of piromelatine (5, 20, and 50 mg daily for 6 months) versus placebo to determine an effective dose based on efficacy (cognitive performance), safety and tolerability in patients with mild dementia due to AD.
Novartis – ASSESS: Relapsing-Remitting MS
A one-year study to compare efficacy and safety of 2 doses of oral Fingoli mod (Gilenya) to Copaxone in adults at least 18 years old with rela psing remitting multi ple sclerosis.
Sanofi IVSS: OBS14379
A prospective observational cohort study in adult patients with relapsing multiple sclerosis to assess patient safety during and after LEMTRADA® (alemtuzumab) infusions of the first treatment course
Seratrials – 05035
One time blood draw for patients with multiple sclerosis – Amex gift card to those that qualify. There are a few projects: (1) MS with EDSS 1.5 or less (2) MS with EDSS 3.0 or more (3) RRMS currently taking Copaxone
Sun Pharma – SPASTICITY: Spasticity Due to MS
A 22-week study evaluating a new formulation of extended release baclofen in patients 18 years old and older with spasticity due to multiple sclerosis.
Sun Pharma – SPASTICITY OL: Spasticity Due to MS
A long-term safety study evaluating a new formulation of extended release baclofen in patients 18 years old and older with spasticity due to MS, who completed 26 weeks of treatment in the spasticity trial.
Suven Life Sciences Ltd: Moderate Alzheimer’s disease (MMSE 12-20)
26-week long study to evaluate the safety and efficacy of SUVN-502 with donepezil and memantine for the treatment of moderate Alzheimer’s disease.
TransTech Pharma: Mild Alzheimer’s Disease (STEADFAST) (MMSE 21-26)
An 18-month long study testing the efficacy and safety of an investigational medication on improving memory in patients with mild Alzheimer’s disease, age 50 and over, currently taking AChEI (donepezil, rivastigmine, galantamine) or memantine.